stockrow
Friday 6 November 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
0.94
0.04
+4.44%
Follow GUTS
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(518.40%) | (744.17%) | (778.33%) | 1,063.04% | |
| (101.33%) | (122.85%) | (118.41%) | (146.75%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(191.82%) | (196.71%) | (205.18%) | (295.82%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(16.12) | (14.39) | (6.64) | (6.24) | |
Free Cash Flow |
(86.81) | (90.88) | (87.73) | (82.43) | |
Capital Expenditures |
(0.79) | (0.56) | — | — | |
| Other line items | |||||
Cash ROIC |
(82.48%) | (74.75%) | (76.50%) | (108.57%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.70 | 0.64 | 0.81 | 0.78 | |
Depreciation/Fixed assets |
0.40 | 0.47 | 0.53 | 0.61 | |
Capex/Depreciation |
(0.73) | (0.49) | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(15.97) | (14.30) | (6.64) | (6.24) | |
Capex per Share |
(0.15) | (0.09) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — |
Columns are period end dates · fundamentals updated 2 Nov 2026